Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9613229 | 0.83 | GPR35 (0.48) | CCR2GPR35ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL708036 | 0.81 | CCR2 (0.63) | CCR2GPR35ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL9613261 | 0.80 | PTGES (0.47) | CCR2ABCB11GPR35KDM4EALDH1A1 | |
| SCHEMBL23053008 | 0.77 | CCR2 (0.60) | CCR2ABCB11GPR35F10KDM4E | |
| SCHEMBL15712747 | 0.77 | CCR2 (0.74) | CCR2ABCB11GPR35F10 | |
| SCHEMBL23053024 | 0.76 | CCR2 (0.55) | CCR2GPR35KDM4EALDH1A1HPGD | |
| SCHEMBL1490111 | 0.75 | BRPF1 (0.53) | CCR2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL20909820 | 0.74 | CCR9 (0.55) | CCR2GPR35ALDH1A1 | |
| SCHEMBL6969376 | 0.72 | HSD17B10 (0.66) | CCR2GPR35KDM4EALDH1A1HPGD | |
| SCHEMBL6302599 | 0.72 | CCR2 (1.00) | CCR2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2335700-A1 | Hepatitis C virus polymerase inhibitors with a heterobicylic structure | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2011-06-22 | — | — | EP | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7576079-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-08-18 | — | — | US | disclosed |
| EP-1414797-B9 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYLIC STRUCTURE | BOEHRINGER INGELHEIM CA LTD (CA) | 2009-04-15 | — | — | EP | disclosed |
| US-20090087409-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-04-02 | — | — | US | disclosed |
| EP-1891951-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-02-27 | — | — | EP | disclosed |
| EP-1414797-B1 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYLIC STRUCTURE | BOEHRINGER INGELHEIM CA LTD (CA) | 2008-01-02 | — | — | EP | disclosed |
| US-7141574-B2 | Series of fused heterocycle compounds having improved inhibitory activity against HCV polymerase; hepatitis treatment | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-11-28 | — | — | US | disclosed |
| US-20060160798-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-07-20 | — | — | US | disclosed |
| US-6841566-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM, LTD. (CA) | 2005-01-11 | — | — | US | disclosed |
| US-20040024190-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-02-05 | — | — | US | disclosed |
| US-20030236251-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087409-A1 | Viral Polymerase Inhibitors | NR2C2, NR4A1, MED25 | CCR2 400/4885ABCB11 2409/4885GPR35 2444/4885 |
| US-20030236251-A1 | Viral polymerase inhibitors | POLR2H, CTDSP1, POLR2E | CCR2 223/4885ABCB11 3925/4885GPR35 4096/4885 |
| US-20060160798-A1 | Viral polymerase inhibitors | NR4A1, NR1I3, RER1 | CCR2 403/4885ABCB11 2525/4885GPR35 1948/4885 |
| US-20040024190-A1 | Viral polymerase inhibitors | RCOR1, NR4A1, RER1 | CCR2 542/4885ABCB11 1299/4885GPR35 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.